Respiratory Drug Delivery VIII

The eighth biennial Respiratory Drug Delivery Conference, hosted by Virginia Commonwealth University School of Pharmacy, drew an international crowd in Tucson, Arizona on May 12-16, 2002. More than 625 conference attendees including 125 scientific poster presenters and 50 suppliers gathered in Arizona to exchange the latest developments in the area of drug delivery to the lungs, making this year’s conference the largest in its history. The scientific program ran for four days, and individual sessions targeted:

• Development of Inhaled Steroids - Past, Present and Prospects
• Inhaler Therapeutics - Novel Compounds for Local Action
• Macromolecular Therapeutics - Insulin
• Systemic Drug Delivery: Issues and Challenges in a Changing Environment
• Rationalized Testing for Dose Uniformity, Extractables and Particle Size
• Inhaler Safety, Efficacy, Sales and Drug Deposition - Functions of Device Design?
• New Formulations and Techniques for Improved Drug Delivery
• Powder Innovations

The pre-prints of all podium sessions and posters were published by Davis Horwood International Publishing and are also available electronically on RDD Online.

A complete list of all of the Scientific Poster presentations can be found in RDD VIII Proceedings. They cover a broad selection of topics related to pulmonary and nasal drug delivery, and each one has been peer reviewed. In addition, our Table Exhibition includes over 50 companies encompassing all aspects of inhaled drug delivery technology.

A special thanks to the sponsors of RDD VIII 2002

3M Drug Delivery Systems, Abbott Laboratories, Aeropharm Technology, Aradigm Corporation, AstraZeneca, Aventis Pharma, Battelle Pulmonary Therapeutics, Bespak, Boehringer Ingelheim, Chiesi Farmaceutici, Chiron Corporation, Chrysalis Technologies, Copley Scientific, CTBR (A Member of the Inveresk Research Group), DuPont Fluoroproducts, Elan Drug Delivery, Forest Laboratories, Hoffman-La-Roche, Inhale Therapeutic Systems, Magellan Labortories, MSP Corporation, Novartis, Pamasol Willi Mader AG/DH Industries, Pfizer, Pharmaceutical Profiles, PPD Development Division of PPD Incorporated, Profile Therapeutics, Schering-Plough Corporation, Sofotec GmbH, Solvay Fluorides, Valois Pharma, Vectura Limited, Whitehall Robins